SENSOMEDICAL
Yokneam, Israel· Est.
Sensomedical accelerates neuro‑device commercialization with integrated R&D, prototyping, and regulatory services.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Sensomedical accelerates neuro‑device commercialization with integrated R&D, prototyping, and regulatory services.
Alzheimer's diseaseAnxietyDementiaDepressive disordersEpilepsyMultiple sclerosisObesityParkinson's diseaseSleep disordersVision disordersNeurowellnessDigital health
Technology Platform
Proprietary neuro‑technology platforms (BIOPOT3, BIOCHEM, BIOSTIM) that integrate hardware, software, cloud analytics and manufacturing to accelerate wearable and implantable brain‑device development.
Opportunities
Rising demand for wearable brain‑monitoring and closed‑loop stimulation devices, combined with Sensomedical’s rapid, integrated development model, offers strong growth potential across neuro‑degenerative and psychiatric markets.
Risk Factors
Regulatory approval timelines, high capital requirements for scaling implantable devices, and competition from larger med‑tech firms could constrain growth.
Competitive Landscape
Key competitors include Medtronic, Blackrock Microsystems, and NeuroPace; Sensomedical differentiates itself through its end‑to‑end service platform that shortens development cycles and reduces costs for client innovators.